PRI Drops Suit Against Top Two FCRF Staff; Gilden, Compton Accept “Partnership” Offers
In Brief: Hatch Bill Would Require NDA Sponsors To Pay Fee; IND, Generic Drug NDAs Would Be Exempt
NCI Amends FCRF RFP, Extends Deadline To Nov. 10
Caribbean Conference Reports Incidence Differences With U.S.
Malone Retires As NIH Deputy, Raub To Succeed Him
Eight Win ASCO Young Investigator Awards
Niccotine Reports As Aiding Metastasis
President, Congress, Cancer Letter Take Off
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
